Connect with us

Business

Aurora Cannabis Inc. 2027 Q1 – Results – Earnings Call Presentation (TSX:ACB:CA) 2026-08-08

Published

on

OneWater Marine Inc. (ONEW) Q1 2026 Earnings Call Transcript

This article was written by

Seeking Alpha’s transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team

Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Business

Week Ahead: Soft CPI To Follow Disappointing U.S. Jobs Report

Published

on

Week Ahead: Soft CPI To Follow Disappointing U.S. Jobs Report

Week Ahead: Soft CPI To Follow Disappointing U.S. Jobs Report

Continue Reading

Business

Essential Properties Realty Trust Is Getting Close To A Buy Rating

Published

on

Whale's Insight: A Macro-Driven Market With No Safe Haven, And No End To Volatility

Essential Properties Realty Trust Is Getting Close To A Buy Rating

Continue Reading

Business

Super Group Q2: An Expected Beat-And-Raise Report

Published

on

Super Group Q2: An Expected Beat-And-Raise Report

Super Group Q2: An Expected Beat-And-Raise Report

Continue Reading

Business

Terex: Stability Arrives After Busy Times

Published

on

Terex: Stability Arrives After Busy Times

Terex: Stability Arrives After Busy Times

Continue Reading

Business

Berkshire Hathaway spends down cash pile under CEO Greg Abel

Published

on

Berkshire Hathaway spends down cash pile under CEO Greg Abel
Berkshire Hathaway Inc. spent about $4.5 billion to buy back its own shares in the second quarter and purchased nearly $20 billion of equities in the period, signs that Chief Executive Officer Greg Abel is putting more of the firm’s cash pile to work.

Berkshire started buying back its own shares in the first quarter for the first time in more than a year. Earlier this year, Abel said Berkshire was restarting buybacks because executives found the “intrinsic value” of those shares exceeded their market price.

“People are going to be encouraged by the buybacks,” said Cathy Seifert, an analyst for CFRA Research. “It’s also Greg’s way of taking the helm and asserting himself.”

The stock buybacks provided shareholders with their largest quarterly payout since 2021. The firm’s cash hoard fell to $365.5 billion in the second quarter, down from roughly $397 billion in the prior period.

Advertisement

Operating earnings climbed 16% in the three months through June to nearly $13 billion, driven in part by gains in the conglomerate’s manufacturing, service and retailing division, as well as at its utilities business, the Omaha, Nebraska-based company said Saturday in a statement.


Berkshire’s earnings are typically closely watched because its businesses — ranging from insurance to railroads to energy and manufacturing — provide a snapshot of the health of the US economy.
After years of relatively quiet deal activity under Warren Buffett, who often complained of high market valuations, his successor sealed back-to-back multibillion-dollar transactions.The newly minted CEO spent $6.8 billion to buy homebuilder Taylor Morrison Home Corp., a typical value bet, while also handing $10 billion to Google parent Alphabet Inc. to support its investments related to artificial intelligence, a new area for the conglomerate.

The deal puts Alphabet among Berkshire’s top five holdings at the end of the quarter, replacing Chevron Corp. The Taylor Morrison transaction closed in the third quarter.

Halfway through his first year at the helm of Berkshire Hathaway, Abel has been praised by shareholders for his leadership.

Still, Berkshire’s Class B shares rose 3.8% this year as of market close Friday, compared with a roughly 13% gain for the S&P 500 — a benchmark that Buffett himself frequently cited.

Advertisement

Operational Improvements

Net income at Berkshire’s railroad unit BNSF rose 6.3% to about $1.6 billion amid higher shipping volumes, despite higher fuel costs. BNSF CEO Katie Farmer has been charged with improving the unit’s operating margin and closing the gap with its most efficient peers.

Geico, the main contributor to Berkshire’s insurance results, posted pretax underwriting earnings that fell by 45%, to $994 million, in the second quarter amid higher losses and an increase in commissions and advertising expenses.

“This is in sharp contrast to what we’re seeing at some other underwriters” that are struggling with sales because of competition but still reporting “some really strong underwriting profits,” Seifert said.

The decline more than offset gains at Berkshire’s other primary insurance and reinsurance businesses, resulting in a 13% decline in net underwriting income for the entire insurance group to $1.7 billion.

Advertisement

Over the period, net income at the conglomerate’s collection of manufacturing, service and retailing units jumped 24% to $4.5 billion, while profits at Berkshire’s utilities business surged 27%, to $891 million.

Continue Reading

Business

Yemen’s Houthis say they attacked Saudi Aramco Jazan refinery, fire extinguished

Published

on


Yemen’s Houthis say they attacked Saudi Aramco Jazan refinery, fire extinguished

Continue Reading

Business

European laggards are rebounding – how far can they go?

Published

on


European laggards are rebounding – how far can they go?

Continue Reading

Business

BlackSky Finally Delivers (NYSE:BKSY) | Seeking Alpha

Published

on

BlackSky Finally Delivers (NYSE:BKSY) | Seeking Alpha

This article was written by

I hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciation for the rigor and challenges behind drug development, which I now bring into my work as an investor and analyst. For the past five years, I have been active in the investing space, with the last four years dedicated to working as a biotech equity analyst alongside my lab work. My focus is on identifying promising biotechnology companies that are innovating in unique and differentiated ways, whether through novel mechanisms of action, first-in-class therapies, or platform technologies with the potential to reshape treatment paradigms. By combining my lab-based scientific expertise with financial and market analysis, I aim to deliver research that is both technically sound and investment-driven. On Seeking Alpha, I plan to write primarily about the biotech sector, covering companies at different stages of development, from early clinical pipelines to commercial-stage biotechs. My approach emphasizes evaluating the science behind drug candidates, the competitive landscape, clinical trial design, and the potential market opportunity, all while balancing financial fundamentals and valuation. My goal in publishing here is to share some insights that help investors better understand both the opportunities and of course the many risks in biotech. This is a sector where breakthrough science can translate into outsized returns, but also where careful scrutiny is essential. I look forward to contributing thoughtful analysis and engaging with readers who share an interest in this dynamic and rapidly evolving space.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Advertisement
Continue Reading

Business

Banks Lead a Bonus Boom

Published

on

Banks Lead a Bonus Boom

Wall Street’s year-end bonuses are looking robust after the second quarter, with some lucky souls seeing as much as 15% above 2025. Compensation consultant Johnson Associates dubs it “The Year of the Bank” in a recent report, with year-end incentive pools 5% to 20% higher than 2025 at major investment and commercial banks. “Everything is shaping up to be a fantastic year for the banks,” says the firm’s managing director Chris Connors. “They really are firing on all cylinders.”

Continue Reading

Business

Ukraine drone attacks put Russia’s Wildberries and banks under pressure

Published

on


Ukraine drone attacks put Russia’s Wildberries and banks under pressure

Continue Reading

Trending

Copyright © 2025